Trovagene Inc. (NASDAQ:TROV) has earned an average rating of “Hold” from the nine analysts that are currently covering the stock. Five research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $6.45.

A number of equities analysts recently weighed in on the stock. Cantor Fitzgerald raised shares of Trovagene from a “hold” rating to a “buy” rating and upped their target price for the stock from $5.00 to $7.00 in a research note on Monday, August 8th. Zacks Investment Research lowered shares of Trovagene from a “buy” rating to a “hold” rating in a research note on Tuesday, September 20th. Maxim Group reaffirmed a “buy” rating and issued a $9.00 target price on shares of Trovagene in a research note on Thursday, October 6th. Finally, Piper Jaffray Cos. set a $4.00 target price on shares of Trovagene and gave the stock a “hold” rating in a research note on Friday, August 5th.

Large investors have recently modified their holdings of the company. California State Teachers Retirement System boosted its stake in shares of Trovagene by 1.0% in the third quarter. California State Teachers Retirement System now owns 59,677 shares of the company’s stock valued at $268,000 after buying an additional 600 shares during the period. Rhumbline Advisers boosted its stake in shares of Trovagene by 1.7% in the third quarter. Rhumbline Advisers now owns 39,841 shares of the company’s stock valued at $179,000 after buying an additional 670 shares during the period. Northern Trust Corp boosted its stake in shares of Trovagene by 1.0% in the third quarter. Northern Trust Corp now owns 312,732 shares of the company’s stock valued at $1,404,000 after buying an additional 2,978 shares during the period. BlackRock Investment Management LLC boosted its stake in shares of Trovagene by 5.6% in the second quarter. BlackRock Investment Management LLC now owns 113,232 shares of the company’s stock valued at $513,000 after buying an additional 5,964 shares during the period. Finally, Princeton Capital Management Inc. boosted its stake in shares of Trovagene by 22.2% in the third quarter. Princeton Capital Management Inc. now owns 84,670 shares of the company’s stock valued at $380,000 after buying an additional 15,400 shares during the period. 29.87% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Trovagene (NASDAQ:TROV) opened at 3.00 on Monday. The firm’s market capitalization is $91.85 million. Trovagene has a 12 month low of $2.85 and a 12 month high of $7.18. The stock has a 50 day moving average price of $3.75 and a 200 day moving average price of $4.61.

TRADEMARK VIOLATION WARNING: “Trovagene Inc. (TROV) Receives $6.45 Average Price Target from Brokerages” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of US and international trademark & copyright laws. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2016/11/24/trovagene-inc-trov-receives-6-45-average-price-target-from-brokerages.html.

Trovagene Company Profile

Trovagene, Inc (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.

5 Day Chart for NASDAQ:TROV

Receive News & Stock Ratings for Trovagene Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trovagene Inc. and related stocks with our FREE daily email newsletter.